Patents Represented by Attorney, Agent or Law Firm David L. Berstein
-
Patent number: 6410516Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: GrantFiled: June 5, 1995Date of Patent: June 25, 2002Assignees: President & Fellows of Harvard College, Massachusetts Institute of Technology, Whitehead Instittue for Biomedical ResearchInventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. Lebowitz, Albert S. Baldwin, Jr., Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
-
Patent number: 6306649Abstract: This invention provides novel materials and methods involving the heterologous expression of transcription factors which are useful for effecting transcription of target genes in genetically engineered cells or organisms containing them. Target gene constructs and other materials useful for practicing the invention are also disclosed.Type: GrantFiled: June 27, 1996Date of Patent: October 23, 2001Assignee: ARIAD Gene Therapeutics, Inc.Inventors: Michael Z. Gilman, Sridaran Natesan
-
Patent number: 6303319Abstract: The present invention provides methods and compositions for identifying inhibitors of the interaction between phosphopeptide binding pairs, i.e., a protein domain having at least one phosphopeptide binding domain and the phosphorylated ligands that bind these domains. These inhibitors may be used for pharmaceutical compositions and in therapeutic treatments for diseases in which a phosphopeptide domain binding is implicated.Type: GrantFiled: July 15, 1998Date of Patent: October 16, 2001Assignee: ARIAD Pharmaceuticals, Inc.Inventor: Richard J. Rickles
-
Patent number: 6258823Abstract: This invention concerns derivatives of rapamycin and their antifungal uses. Also disclosed are materials and methods relevant to the identification of non-immunosuppressive antifungal rapamycin derivatives.Type: GrantFiled: November 2, 1998Date of Patent: July 10, 2001Assignee: Ariad Pharmaceuticals, Inc.Inventors: Dennis A. Holt, Terence P. Keenan, Timothy P. Clackson, Leonard Rozamus, Wu Yang, Michael Z. Gilman
-
Patent number: 6207397Abstract: An in vitro assay method permits the identification of a test substance which inhibits the mutual association of two molecules. The method includes the steps of providing two components capable of mutual association, one of said components bearing a covalently linked fluorophore; preparing a mixture containing the two components and at least one test substance; irradiating the mixture with polarized light of a suitable wavelength permitting excitation of the fluorophore as indicated by emission of polarized light; measuring the degree of polarization of the emission, and determining the effect of the presence or concentration of the test substance in decreasing the observed emission polarization of a mixture of the two components alone. Inhibitory activity of the test substance correlates with decreased depolarization values.Type: GrantFiled: October 22, 1997Date of Patent: March 27, 2001Assignee: ARIAD Pharmaceuticals, Inc.Inventors: Berkley A. Lynch, Ian MacNeil, Mark Zoller
-
Patent number: 6187757Abstract: Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.Type: GrantFiled: January 22, 1998Date of Patent: February 13, 2001Assignee: ARIAD Pharmaceuticals, Inc.Inventors: Timothy P. Clackson, Michael Z. Gilman, Dennis A. Holt, Terence P. Keenan, Leonard Rozamus, Wu Yang
-
Patent number: 6165787Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.Type: GrantFiled: May 29, 1998Date of Patent: December 26, 2000Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
-
Patent number: 6140120Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .xi.Type: GrantFiled: September 16, 1998Date of Patent: October 31, 2000Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Steffan N. Ho, Peter Belshaw
-
Patent number: 6133456Abstract: New compounds are disclosed for multimerizing immunophilins and proteins containing immunophilin or immunophilin-related domains. The compounds are of the formulaM.sup.1 --L--M.sup.2where M.sup.1 and M.sup.2 are independently moieties of the formula: ##STR1## in which B.sup.1, B.sup.2, B.sup.3, R.sup.1, R.sup.2, n, W, X and Y are as defined.Type: GrantFiled: February 28, 1997Date of Patent: October 17, 2000Assignee: ARIAD Gene Therapeutics, Inc.Inventors: Dennis A. Holt, Terence P. Keenan, Tao Guo, Edgardo Laborde, Wu Yang
-
Patent number: 6117680Abstract: The present invention relates to novel fusion proteins which activate transcription, to nucleic acid constructs encoding the proteins and their use in the genetic engineering of cells.Type: GrantFiled: August 26, 1998Date of Patent: September 12, 2000Assignee: ARIAD Gene Therapeutics, Inc.Inventors: Sridaran Natesan, Michael Z. Gilman
-
Patent number: 6063625Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.Type: GrantFiled: September 16, 1998Date of Patent: May 16, 2000Assignees: Board of Trustees of Leland S, Stanford, Jr. University, President and Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Steffan N. Ho, Peter Belshaw
-
Patent number: 6054436Abstract: We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.Type: GrantFiled: May 29, 1998Date of Patent: April 25, 2000Assignees: Board of Trustees of Leland S. Stanford Jr. Univ., President & Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
-
Patent number: 6046047Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of tis invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.Type: GrantFiled: September 16, 1998Date of Patent: April 4, 2000Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw, Steffan N. Ho
-
Patent number: 6043082Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.Type: GrantFiled: September 16, 1998Date of Patent: March 28, 2000Assignees: Board of Trustees of Leland Stanford Jr. Univ., President & Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Steffan N. Ho, Peter Belshaw
-
Patent number: 6015709Abstract: The present invention relates to chimeric transcriptional activators.Type: GrantFiled: August 27, 1997Date of Patent: January 18, 2000Assignee: ARIAD Pharmaceuticals, Inc.Inventor: Sridaran Natesan
-
Patent number: 6011018Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.Type: GrantFiled: May 29, 1998Date of Patent: January 4, 2000Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
-
Patent number: 5994313Abstract: We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.Type: GrantFiled: June 7, 1995Date of Patent: November 30, 1999Assignees: Board of Trustees of the Leland S. Stanford, Jr. Univ., President and Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
-
Patent number: 5981262Abstract: The molecular cloning of humansyk DNA, compositions containing same and uses thereof are disclosed.Type: GrantFiled: January 31, 1996Date of Patent: November 9, 1999Assignee: Ariad Pharmaceuticals, Inc.Inventors: Joan Brugge, Jay Morganstern, Lily Shiue, Lynne Zydowsky, Mark Zoller, Anthony Pawson
-
Patent number: 5939528Abstract: The invention relates to the human protein FRAP, and in particular to the FKBP12-rapamycin binding domain thereof and to the ternary complex formed by the FRB domain, rapamycin and FKBP12. A new crystalline composition comprising the ternary complex, coordinates defining its three dimensional structure in atomic detail, and uses thereof are disclosed.Type: GrantFiled: October 31, 1997Date of Patent: August 17, 1999Assignee: Cornell Research Foundation, Inc.Inventors: Jon C. Clardy, Jungwon Choi
-
Patent number: 5871753Abstract: Methods and compositions are provided for modified cells, where a chimeric protein consisting of a ligand binding domain fused to an action domain is employed which initiates a signal which activates a biological process: transcription of at least one gene, usually a second construct introduced into the host cells; exocytosis; or an extracellular process. The second construct optimally present provides for a promoter which responds to a transcriptional activation action domain to provide for transcription, when an appropriate ligand binds to the ligand binding domain. Exemplary of the system is the use of an FKBP/CD3.zeta. or transcription factor fusion protein, using dimeric FK506 or FK520 as the ligand and a promoter responsive to NF-AT or other transcription factor requiring two molecules for transcriptional activation.Type: GrantFiled: June 7, 1995Date of Patent: February 16, 1999Assignees: Board of Trustees of the Leland Stanford Junior University, President and Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw, Steffan Ho